A promising line of defense against ALS has moved into phase 3, as the PREVAiLS study tests pridopidine in early, rapidly progressing patients across a global network of treatment centers.

The trial aims to enroll about 500 participants at up to sixty sites in thirteen countries, reflecting a concerted effort to determine whether this drug can slow the trajectory of a disease that widely devastates motor function and independence.

ALS is a relentlessly progressive disorder in which the brain loses the signals that keep muscles coordinated, gradually diminishing the ability to walk, speak, eat or breathe.

Its toll is measured not only in lost movement but in the erosion of autonomy and dignity, as patients and families adapt to a long arc of physical decline.

Here's What They're Not Telling You About Your Retirement

The first participant in PREVAiLS has already been enrolled at Mass General Brigham, with doctor supervision by Sabrina Paganoni, MD, PhD, co-director of the Mass General Hospital Neurological Clinical Research Institute and the trial’s lead investigator.

This early step signals the study’s readiness to move from theory to clinically meaningful testing.

"Pridopidine is a sigma-1 receptor (S1R) agonist," Paganoni shared in a statement. "The S1R has been shown to play a role in stimulating multiple neuroprotective pathways impaired in neurodegenerative diseases, such as ALS and Huntington’s disease."

The global trial, which will include 500 participants, aims to evaluate the safety and effectiveness of pridopidine in slowing the progression of ALS in early, rapidly progressive patients.

This Could Be the Most Important Video Gun Owners Watch All Year

The trial is expected to take place in up to 60 ALS treatment centers across 13 countries.

This is a follow-up to the phase 2 HEALEY ALS Platform Trial results in 2023, which did not reach its main goal of slowing ALS function over the 24-week study period. That research, however, did see positive results in a subgroup of patients who were early in disease and declining rapidly.

Phase 3 incorporates "key learnings" from phase 2, Paganoni shared, and is expected to determine whether pridopidine is effective as a potential treatment for the disease.

"Enrolling the first participant in this confirmatory study is a milestone in our search for potential new therapeutic options that may help to slow disease progression, preserve function, maintain speech and prolong survival – key aims of early ALS therapy," she said.

"As with all clinical research, definitive conclusions won’t be available until the phase 3 trial is completed and fully analyzed."

"The earlier we can diagnose and treat ALS, the greater the potential to preserve function and maintain quality of life for longer, which is key to making ALS livable until we can cure it," he said in the release.

"It was discouraging to see a lack of overall effect in the phase 2 study population," he said.

"However, we were encouraged to see positive signals emerge from various subgroups, including potential impacts on speech and respiratory function."

Because respiratory decline is a leading cause of ALS morbidity and mortality, even modest preservation of breathing capacity can have a meaningful impact on both quality of life and overall outcomes.

The insights gained from the phase 3 trial will be critical in determining whether these early signals translate into "meaningful, consistent benefits for people with early, rapidly progressing ALS," Dave added.

Participating in ALS research is one of the most powerful ways individuals can contribute to accelerating scientific discovery and making ALS livable until we cure it.

As the disease’s trajectory remains grim for many, a disciplined, evidence driven approach to trial design and patient recruitment is essential.

The medical community recognizes that a cure may be years away, but meaningful advances in slowing progression could restore years of function for some patients and provide a clearer path toward improved quality of life.

The patient and caregiver communities deserve access to rigorous testing and transparent reporting. This phase 3 effort embodies that philosophy by building on prior work, refining patient selection, and prioritizing safety as a baseline for any potential benefit.

It is a reflection of the belief that medical progress is achieved through careful, methodical experimentation carried out with patient safety at the forefront.

The ultimate measure of success will come from the trial’s results, which will inform clinicians on how to apply pridopidine in practice.

Until those data are in, the focus remains on rigorous science, disciplined oversight, and the shared commitment of researchers, patients and families to push forward with integrity and realism.